SCHEMBL2393250

SCHEMBL2393250

O=C(O)C(F)(F)c1ccccc1-c1ccccc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
KCNN4 O15554 5/20 0.42
ACMSD Q8TDX5 1/20 0.39
KCNE1 P15382 1/20 0.38
KCNQ1 P51787 1/20 0.38
MAPT P10636 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PKM P14618 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
HTT P42858 1/20 0.36
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
POLB P06746 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31414989 0.84 KCNN4 (0.52) ALDH1A1HPGDKCNN4KCNE1KCNQ1
SCHEMBL17420795 0.84 KCNN4 (0.52) ALDH1A1HPGDKCNN4KCNE1KCNQ1
SCHEMBL9890797 0.84 KCNN4 (0.49) AKR1C3AKR1C2ALDH1A1HPGDKCNN4
SCHEMBL2397461 0.81 ALDH1A1 (0.45) ALDH1A1HPGDPPARGPPARAMEN1
SCHEMBL13199346 0.80 CES1 (0.46) ALDH1A1HPGDKCNN4CES1PPARG
SCHEMBL2392972 0.79 AKR1C3 (0.43) AKR1C3AKR1C2ALDH1A1KCNN4ACMSD
SCHEMBL2477656 0.76 PDK2 (0.40) AKR1C3AKR1C2ALDH1A1HPGDMAPT
SCHEMBL2393385 0.76 TAAR1 (0.42) AKR1C3AKR1C2ALDH1A1HPGDMAPT
SCHEMBL27925987 0.76 KCNN4 (0.49) AKR1C3AKR1C2ALDH1A1HPGDKCNN4
SCHEMBL9890660 0.75 PDK2 (0.43) ALDH1A1KCNN4MAPTHTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
WO-2010055911-A1 BIPHENYLACETAMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 AKR1C3 191/4885AKR1C2 459/4885ALDH1A1 576/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 AKR1C3 191/4885AKR1C2 459/4885ALDH1A1 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.